We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Uridine Monophosphate
A pyrimidine nucleotide and precursor for brain membrane phospholipids, marketed as a nootropic. The honest picture: nearly all positive HUMAN evidence is for the COMBINATION of uridine + DHA/EPA + choline (the Souvenaid / Fortasyn Connect medical food) in early Alzheimer's — and even there the effect is small. Standalone uridine human evidence is essentially preclinical.
What the evidence says
Most Uridine Monophosphate studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2008–2025 with a typical study size of 101 participants.
Based on 5 studies · 1 meta-analysis · 1 RCT · 115 total participants
Confidence
Moderate confidenceBy outcome
Scores Emerging because positive human evidence exists only for the uridine+DHA+choline combination (Souvenaid) in mild Alzheimer's, with small effects; standalone UMP human data are essentially preclinical.
9 trials ongoing or recruiting · 159 completed on ClinicalTrials.gov
83 of the completed trials have posted results
Registered trials show research momentum for Uridine Monophosphate, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Uridine monophosphate (UMP) is a pyrimidine nucleotide that, together with choline and the omega-3 fatty acid DHA, supplies the precursors brain cells use to build phosphatidylcholine and other membrane phospholipids (the Kennedy pathway).
This 'membrane synthesis' rationale is the basis for its use as a nootropic and in early Alzheimer's disease. The crucial honesty point: the clinical evidence is almost entirely for the COMBINATION, not uridine alone.
The Souvenaid medical food (Fortasyn Connect — uridine monophosphate plus DHA, EPA, choline, phospholipids, B-vitamins, and antioxidants) has been tested in randomized controlled trials in mild Alzheimer's, with small effect sizes on memory in the mildest patients and no effect in mild-to-moderate disease.
Animal studies show UMP — especially combined with DHA — improves memory and raises brain phospholipid levels. But there is essentially NO robust standalone-uridine human efficacy trial for memory or neuroprotection.
So UMP is mechanistically reasonable and part of a modestly-evidenced combination product, but on its own it is an emerging, largely preclinical supplement.
Supplies uridine for the Kennedy pathway, providing precursors (with choline and DHA) for phosphatidylcholine and synaptic membrane formation.
Uridine and its nucleotides act on P2Y receptors and may influence neuronal signaling — mechanistic, not yet a proven clinical effect.
How Uridine Monophosphate works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use caution — nucleotide metabolism could theoretically affect uric acid.
Not studied — avoid.
Older reports suggest uridine/nucleotide supplementation could theoretically interact with Parkinson's medication; data are limited — use caution.
Tip: Take with food; reduce dose
Uridine Monophosphate has an evidence score of 3/10 — emerging evidence based on 4 indexed studies, including 1 meta-analysis. A pyrimidine nucleotide and precursor for brain membrane phospholipids, marketed as a nootropic. The honest picture: nearly all positive HUMAN evidence is for the COMBINATION of uridine + DHA/EPA + choline (the Souvenaid / Fortasyn Connect medical food) in early Alzheimer's — and even there the effect is small. Standalone uridine human evidence is essentially preclinical. Representative study: PMID 27767993.
The commonly studied dose of Uridine Monophosphate is No human-trial-validated standalone dose; nootropic users commonly take 150-500 mg/day. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Uridine Monophosphate is with meals. Take it with food. Often taken with food; note that no standalone-UMP human efficacy trial anchors this dose.
Uridine Monophosphate is generally safe at recommended doses, with a few precautions worth noting. Reported side effects are uncommon and include mild GI upset or headache. Use caution if any of these apply to you: Pregnancy/breastfeeding (not studied); Gout / hyperuricemia (theoretical — uridine is a nucleotide and could affect purine/pyrimidine metabolism).
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Citicoline
Probably helpsDual precursor to acetylcholine and phosphatidylcholine — enhances memory, focus, and brain cell membrane repair.
Huperzine A
Likely helpsAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Phosphatidylserine
Mostly mechanism / observationalKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 5 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research